Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 2

Scientists Recreate Rare Pigment Behind Octopus ‘Superpowers’

Octopuses and other cephalopods are masters of camouflage, thanks largely to color-changing skin that can help them seemingly vanish into the background. Now, researchers report a big step towards being able to recreate their superpower.

A team led by UC San Diego was able to mass-produce a key pigment, xanthommatin, that occurs in the psychedelic skin of many cephalopods. Until now, xanthommatin has proven impractical to collect from animals or make in a lab.

The researchers technically didn’t make the pigment. They bioengineered bacteria to make it, coaxing microbes to not only produce this rare substance, but to do so with unprecedented efficiency, yielding up to 1,000 times more xanthommatin than previous methods.

As brain organoids grow increasingly complex, leading scientists and bioethicists call for global oversight

In an effort to address these ethical grey areas, 17 leading scientists and bioethicists from five countries are urging the establishment of an international oversight body to monitor advances in the rapidly expanding field of human neural organoids and to provide ethical and policy guidance as the science continues to evolve. The call to action, published Thursday in Science, comes as U.S. government agencies are making new investments in organoid science aimed at accelerating drug discovery and reducing reliance on animal models of disease.

In September, the National Institutes of Health announced $87 million in initial contracts to establish a new center dedicated to standardizing organoid research. The move followed an earlier pledge by both the NIH and the Food and Drug Administration to reduce, and possibly replace, testing on mice, primates, and other animals with other methods — including organoids and organ-on-a-chip technologies — for developing certain medicines.

Government promotion of human stem cell models more broadly will only increase the recruitment of new researchers into the field of neural organoids, which has seen an explosion from a few dozen labs a decade ago to hundreds around the world now, said Sergiu Pasca, a pioneering neuroscientist and stem cell biologist at Stanford University who co-authored the Science commentary.

Goodbye, Cavities? Scientists Just Found a Way to Regrow Tooth Enamel

A newly developed material has been used to create a gel capable of repairing and rebuilding tooth enamel, offering a potential breakthrough in both preventive and restorative dental care.

Scientists from the University of Nottingham’s School of Pharmacy and Department of Chemical and Environmental Engineering designed this bioinspired substance to restore damaged or eroded enamel, reinforce existing enamel, and help guard against future decay. Their findings were published in Nature Communications.

This protein-based gel, which contains no fluoride, can be quickly applied to teeth using the same method dentists use for traditional fluoride treatments. It imitates the natural proteins responsible for guiding enamel formation early in life. Once in place, the gel forms a thin, durable coating that seeps into the tooth surface, filling small cracks and imperfections.

MIT researchers invent new human brain model to enable disease research, drug discovery

A new 3D human brain tissue platform developed by MIT researchers is the first to integrate all major brain cell types, including neurons, glial cells, and the vasculature, into a single culture.

Grown from individual donors’ induced pluripotent stem cells, these models — dubbed Multicellular Integrated Brains (miBrains) — replicate key features and functions of human brain tissue, are readily customizable through gene editing, and can be produced in quantities that support large-scale research.

Although each unit is smaller than a dime, miBrains may be worth a great deal to researchers and drug developers who need more complex living lab models to better understand brain biology and treat diseases.

Nobel winner’s lab notches another breakthrough: AI-designed antibodies that hit their targets

Researchers from Nobel Laureate David Baker’s lab and the University of Washington’s Institute for Protein Design (IPD) have used artificial intelligence to design antibodies from scratch — notching another game-changing breakthrough for the scientists and their field of research.

“It was really a grand challenge — a pipe dream,” said Andrew Borst, head of electron microscopy R&D at IPD. Now that they’ve hit the milestone of engineering antibodies that successfully bind to their targets, the research “can go on and it can grow to heights that you can’t imagine right now.”

Borst and his colleagues are publishing their work in the peer-reviewed journal Nature. The development could supercharge the $200 billion antibody drug industry.

Nanoparticle Treatment Reverses Alzheimer’s in Mice

Scientists have developed a nanoparticle-based treatment that successfully reversed Alzheimer’s disease in mice.

As detailed in a new paper published in the journal Signal Transduction and Targeted Therapy, the team co-led by the Institute for Bioengineering of Catalonia, Spain (IBEC), and West China Hospital, Sichuan University, developed bioactive “supramolecular drugs” that can proactively repair the blood-brain barrier.

The barrier plays an important role in the health of the brain, defending it from harmful substances and other pathogens. Alzheimer’s has been linked to a weakening of the barrier’s integrity, allowing for impairing toxins to make it through.

From blood to solid tumors: A new way to power up CAR T cell therapy

Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of all adult cancers, remain a major challenge because they are difficult for CAR T cells to infiltrate and are often highly heterogeneous, making them harder to target with a single therapy.

Researchers at Monash University, in collaboration with scientists from the Peter MacCallum Cancer Center, used CRISPR-based gene editing or a PTPN2 inhibitor to enhance the function of human CAR T cells engineered to recognize an antigen expressed on many .

The study, led by Professor Tony Tiganis and Dr. Florian Wiede, was published in Science Translational Medicine.

Scientist Solves 100-Year-Old Physics Puzzle To Track Airborne Killers

Researchers at the University of Warwick have created a straightforward new way to predict how irregularly shaped nanoparticles, a harmful type of airborne pollutant, move through the air.

Each day, people inhale countless microscopic particles such as soot, dust, pollen, microplastics, viruses, and engineered nanoparticles. Many of these particles are so small that they can reach deep into the lungs and even pass into the bloodstream, where they may contribute to serious health problems including heart disease, stroke, and cancer.

While most airborne particles have uneven shapes, existing mathematical models often treat them as perfect spheres because that makes the equations easier to handle. This simplification limits scientists’ ability to accurately describe or track how real, non-spherical particles move, especially those that are more dangerous.

The Cyborg Child: SCP-191 and the Ethics of Human Evolution

What happens when the pursuit of perfection forgets compassion?
SCP-191, known as The Cyborg Child, is one of the most haunting examples of speculative bioengineering ever documented. This essay examines the anatomy, psychology, and philosophy of a child transformed into a machine — a being caught between humanity and technology.

In this episode, we explore:

How cybernetic modification redefines the human body.

The science behind hybrid consciousness and neural integration.

The moral cost of evolution without empathy.

What SCP-191 reveals about the posthuman future.

Continue reading “The Cyborg Child: SCP-191 and the Ethics of Human Evolution” | >

Automated chloroplast screening platform speeds up crop trait development

Chloroplasts—the “light power plants” of plant cells—are increasingly the focus of synthetic biology. These organelles house the photosynthetic apparatus and host several metabolic pathways that are of great interest for engineering new traits. Gene insertion into chloroplasts is precise and carries a lower risk of transgene escape.

Despite this potential, chloroplast biotechnology remains in its infancy because standardized, scalable methods for rapid testing of diverse genetic parts have been missing. A research team from the Max Planck Institute for Terrestrial Microbiology in Marburg has now presented a micro‑algal platform that allows automated, fast, and large‑scale testing of chloroplast genetic modifications.

The study is published in the journal Nature Plants.

/* */